IMMUNOTHERAPY PUBLICATIONS & ABSTRACTS
Immunotherapy Data
Evidence / Immunotherapy
Genomically Basal-Type tumors demonstrate distinct immune profiles and chemosensitivity across self-reported race among patients enrolled in FLEX receiving neoadjuvant chemotherapy
Publication: ASBrS 2026, Abstract Number: 1062 Authors:Nathalie Johnson, Mehran Habibi, Marcela Mazo, Ahmed Elkhanany, Fengting Yan, Nicole Sookhan, J. Jaime Alberty-Oller, Laila Samiian, Eric Brown, Linsey Gold, Alfredo Santillan, Eduardo Dias, Sasha Davis, Laura Lee, Constantine Godellas, Abigail Beard, Gordan Srkalovic, Beth-Ann Lesnikoski, Sahra Uygun, Christina Page, Nicole Stivers, Read More
Incorporating Immunotherapy in the Management of Early-Stage Estrogen Receptor-Positive Breast Cancer
Publication: ESMO Open - Volume 9 - Issue 11 - 2024 1 Authors: G. Nader-Marta, A. G. Waks, S. M. Tolaney, E. L. Mayer Title: Incorporating immunotherapy in the management of early-stage estrogen receptor-positive breast cancer Abstract Immune checkpoint inhibitors (ICI) have been incorporated into standard treatment regimens for Read More
Case Report: pCR to NAC + Pembro in High Risk Basal-type BC
Cureus, part of Springer Nature Author: Jiang et al.
Read MoreNeoadjuvant CT & Immunotherapy in HR+/HER2-negative breast cancer
Journal of Clinical Oncology, April 9, 2024 Presenter: Rios-Hoyo et al.
Read MoreIMPRINT-TN: Triple-Negative Breast Cancer, Unlikely to Respond to Immunotherapy
2024 European Breast Cancer Conference (EBCC) (Abstract 2LBA) Presenter: Wolf et al.
Read MoreImPrint immune signature in 10,000 early stage breast cancer patients from FLEX Study
SABCS 2022, Poster ID: PD9-08 Authors: Brufsky et al.
Read MoreI-SPY2: ImPrint immune signature identifies ESBC patients who benefit from PD1 checkpoint inhibition
ASCO 2022, Poster #514 Authors: Kuilman et al.
Read More
